Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...
Investor's Business Daily on MSN7d
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...
Scotiabank starts Viking Therapeutics at Outperform, sees attractive entry point
As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...
Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress
CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...
Business Insider28d
Viking Therapeutics’ VK2735: A Promising Contender in the Weight-Loss Market with Superior Efficacy Profile
The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735 ... Premium journey today. Viking Therapeutics (VKTX) Company Description: Viking ...